Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words "believes," "expects," "anticipates," "plans," "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the statements made by the Company and by its partner Auxilium regarding the availability of a XIAFLEX specific CPT code; the ability of Pfizer to achieve its objectives for XIAPEX in Europe; the success of the Phase III trials for XIAFLEX for the treatment of Peyronie's disease, which will determine the amount of milestone, royalty and sublicense income payments the Company may receive; the outcome of the dispute with Auxilium; the Company's ability to restart the Chien-803 trial; the Company's ability to initiate and complete clinical trials in additional indications; and other risk factors identified in the Company's Form 10-K for the year ended December 31, 2009 and its reports on Form 8-K filed with the U.S. Securities and Exchange Commission. All forward-looking statements included in this press release are made as of the date hereof, and the Company assumes no obligation to update these forward-looking statements. BioSpecifics Technologies Corp.Consolidated Statements of OperationsThree months endedTwelve months endedDecember 31December 312010200920102009Revenues:(Unaudited)(Audited)
|SOURCE BioSpecifics Technologies Corp.|
Copyright©2010 PR Newswire.
All rights reserved